Efficacy Outcomes From 3 Clinical Trials of Edivoxetine as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment

Susan G. Ball, PhD; Margaret B. Ferguson, PharmD; James M. Martinez, MD; Beth A. Pangallo, RN; E. Serap Monkul Nery, MD; Mary Anne Dellva, MS; JonDavid Sparks, PhD; Qi Zhang, PhD; Peng Liu, PhD; Mark Bangs, MD; and Celine Goldberger, MD

Published: May 25, 2016

Article Abstract

Objective: Three studies examined whether edivoxetine (a highly selective norepinephrine reuptake inhibitor) had efficacy as adjunctive therapy for patients with major depressive disorder (DSM-IV-TR) who were partial responders to selective serotonin reuptake inhibitor (SSRI) treatment of at least 6 weeks’ duration.

Method: Studies were 8-week randomized, placebo-controlled trials with a 3-week double-blind placebo lead-in phase, conducted from December 16, 2010, to October 21, 2013. Patients entered the double-blind adjunctive treatment phase if they met randomization criteria (< 25% improvement on Montgomery-Asberg Depression Rating Scale [MADRS] and MADRS total score ≥ 14); patients not randomized remained on adjunctive placebo. Study 1 compared fixed-dose edivoxetine (12 or 18 mg daily) + SSRI (N = 231 and N = 230, respectively) with placebo + SSRI (N = 240); study 2 compared flexible-dose edivoxetine (12-18 mg daily) + SSRI (N = 232) and fixed-dose edivoxetine (6 mg daily) + SSRI (N = 226) with placebo + SSRI (N = 231); and study 3 compared flexible-dose edivoxetine (12-18 mg daily) + SSRI (N = 230) with placebo + SSRI (N = 219). The primary outcome was mean change from randomization baseline to week 8 in MADRS total score, analyzed using repeated measures analysis.

Results: Each trial failed to meet the primary and most of the secondary objectives. The least-squares mean changes in MADRS total score were as follows—study 1: −8.5 (edivoxetine 12 mg + SSRI), -8.7 (edivoxetine 18 mg + SSRI), and −7.8 (placebo + SSRI); study 2: −9.4 (edivoxetine 12-18 mg + SSRI), −9.6 (edivoxetine 6 mg + SSRI), and −9.4 (placebo + SSRI); and study 3: −8.7 (edivoxetine 12-18 mg + SSRI) and −8.5 (placebo + SSRI).

Conclusions: Adjunctive edivoxetine treatment for patients with major depressive disorder who were partial responders to SSRIs did not significantly improve efficacy outcomes.

Trials Registrations: ClinicalTrials.gov identifiers: NCT01173601, NCT01187407, NCT01185340

Volume: 77

Quick Links: Depression (MDD)

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF


Sign-up to stay
up-to-date today!


Already registered? Sign In

Original Research

Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial

This RCT determined whether a single dose of sublingual dexmedetomidine reduced acute agitation associated with schizophrenia or...